Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Canertinib dihydrochloride (PD-183805 dihydrochloride) 是一种可口服的喹唑啉盐酸盐,具有潜在的抗肿瘤和放射增敏活性,抑制细胞 EGFR 和 ErbB2自身磷酸化的 IC50值分别为 7.4 和 9 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
10 mg | ¥ 457 | 现货 | ||
50 mg | ¥ 698 | 现货 | ||
100 mg | ¥ 996 | 现货 | ||
200 mg | ¥ 1,762 | 待询 | ||
500 mg | ¥ 3,997 | 待询 | ||
1 mL * 10 mM (in DMSO) | ¥ 497 | 现货 |
产品描述 | Canertinib dihydrochloride (PD-183805 dihydrochloride) is the hydrochloride salt of an orally bio-available quinazoline with potential antineoplastic and radiosensitizing activities. |
靶点活性 | EGFR:7.4nM, ErbB2:9 nM |
激酶实验 | Kinase inhibition: Cediranib is dissolved in DMSO at a concentration of 10 mM. All enzyme assays are run at, or just below, the respective Km for ATP (0.2 - 30 μM). The inhibitory activity of Cediranib is determined against a range of recombinant tyrosine kinases [KDR, Flt-1, Flt-4, c-Kit, PDGFRα, PDGFRβ, CSF-1R, Flt-3, FGFR1, Src, Abl, epidermal growth factor receptor (EGFR), ErbB2, Aurora A, and Aurora B] using ELISA. Selectivity versus CDK2 and CDK4 serine/threonine kinases is examined using scintillation proximity assays with a retinoblastoma substrate and [γ-sup>33P]ATP. Activity of Cediranib is compared to MAPK kinase (MEK), which shows dual specificity. It is determined using a MAPK substrate, [γ-33P]ATP, and paper capture/scintillation counting. |
别名 | CI-1033 dihydrochloride, PD-183805 dihydrochloride, Canertinib, 卡奈替尼二盐酸盐 |
分子量 | 558.86 |
分子式 | C24H27Cl3FN5O3 |
CAS No. | 289499-45-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 55.9 mg/mL(100 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.7894 mL | 8.9468 mL | 17.8936 mL | 44.7339 mL |
5 mM | 0.3579 mL | 1.7894 mL | 3.5787 mL | 8.9468 mL | |
10 mM | 0.1789 mL | 0.8947 mL | 1.7894 mL | 4.4734 mL | |
20 mM | 0.0895 mL | 0.4473 mL | 0.8947 mL | 2.2367 mL | |
50 mM | 0.0358 mL | 0.1789 mL | 0.3579 mL | 0.8947 mL | |
100 mM | 0.0179 mL | 0.0895 mL | 0.1789 mL | 0.4473 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Canertinib dihydrochloride 289499-45-2 Angiogenesis JAK/STAT signaling Tyrosine Kinase/Adaptors EGFR ErbB-1 PD 183805 CI-1033 dihydrochloride PD 183805 Dihydrochloride PD-183805 dihydrochloride Orthopoxvirus PD-183805 CI 1033 Dihydrochloride PD183805 Dihydrochloride PD183805 CI1033 Dihydrochloride Epidermal growth factor receptor CI 1033 PD-183805 Dihydrochloride Inhibitor CI1033 Canertinib inhibit 卡奈替尼二盐酸盐 HER1 CI-1033 Canertinib Dihydrochloride CI-1033 Dihydrochloride inhibitor